Navigation Links
Japanese Peripheral Vascular Stent Procedures to Experience 11% Growth Through 2014
Date:12/14/2009

WALTHAM, Mass., Dec. 14 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, Japan's complex regulatory environment and lengthy device approval process has created a significant lag in peripheral vascular stenting device availability in the country compared to other developed nations. MRG's new Japanese Markets for Peripheral Vascular Devices 2010 report finds, however, that recent indication-specific device approvals in Japan will drive peripheral vascular stent procedures to expand at a compound annual growth rate of 11% over the next five years, a step up from the 6% annual growth experienced from 2008 to 2009.

In 2008, the Japanese Ministry of Health, Labour and Welfare granted regulatory approval and reimbursement for Cordis' PRECISE, Japan's first vascular stent indicated for the treatment of carotid artery stenosis. That same year, Japan's first embolic protection device, Cordis' ANGIOGUARD, was also approved for use in conjunction with its carotid stent. Both ev3 and Boston Scientific are expecting to launch their carotid stents and embolic protection devices in Japan sometime in 2010. In 2009, Cordis was again first to receive regulatory approval for use of its PALMAZ GENESIS balloon-expandable stent in the renal artery indication. Because reimbursement is not provided for procedures where stents are used off-label, these indication-specific approvals enable physicians to get reimbursed for these stent procedures, thereby promoting procedure adoption and market growth.

"Although the off-label use of peripheral vascular stents occurs in Japan, this is not common practice due to the strict regulatory environment, as well as the high cost associated with the use of these devices off-label," says Darren Navarro, Analyst at MRG. "Because the approval process for a device can take upwards of several years, some devices will continue to be used off-label due to the lack of approved devices for specific indications. Over the next few years, it is expected that more indication-specific stents will emerge in Japan to meet the growing demand for peripheral vascular stenting in the carotid, renal, and other vascular indications, including the lower extremities."

MRG's new report, Japanese Markets for Peripheral Vascular Devices 2010, provides critical insight into emerging trends that will fuel market growth for peripheral vascular stents, percutaneous transluminal angioplasty balloon catheters, embolic protection devices, inferior vena cava filters, aortic stent grafts, synthetic surgical grafts, and accessory devices through 2014. With detailed analysis of procedures, units, average selling prices, revenues, and competitive dynamics, this report will allow you to identify opportunities, formulate meaningful marketing strategies, and track your competitors.

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack(TM) projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


    For more information, contact:

    Amy Krohn
    Millennium Research Group
    416-364-7776 ext. 101
    akrohn@mrg.net

    Elizabeth Marshall
    Decision Resources Inc.
    781-296-2563
    emarshall@dresources.com

SOURCE Millennium Research Group


'/>"/>
SOURCE Millennium Research Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Japanese Cancer Patients Will Have Access to Compensator-Based IMRT with Opening of .decimal, Inc. Office in Tokyo and Hiring of Key Personnel
2. BioWa Announces Second Japanese License of POTELLIGENT(R) Technology to Otsuka Pharmaceutical
3. The Japanese Cancer Association and Debiopharm Group Present the JCA-Mauvernay Award to Dr Ushijima for his Oncology Research
4. Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
5. Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents
6. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
7. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
8. IDEV(R) Technologies Announces First Patient Enrolled in Multi-Center Clinical Trial of SUPERA(R) PERipheral Stent
9. Lower Extremity Peripheral Vascular Stent and Balloon Catheter Markets to Exceed $180 Million in Europe by 2013
10. U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies SUPERA Peripheral Stent
11. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 The vast ... an outpatient dialysis facility.  Treatments are usually 3 times ... hours per visit, including travel time, equipment preparation and ... patient, but especially grueling for patients who are elderly ... a skilled nursing and rehabilitation centers for some duration ...
(Date:6/23/2016)... FRANKLIN, Tenn. , June 23, 2016 ... for automating, integrating and transforming the patient ... launch of several innovative new products and ... depth of its revenue cycle offerings. These ... establish more efficient workflows, remain compliant in ...
(Date:6/23/2016)... WASHINGTON , June 23, 2016  The ... Pharmaceuticals has joined the health policy research organization ... Steven Romano , MD, senior vice president and ... his company,s representative on the NPC Board of ... are pleased that Mallinckrodt has joined us in ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
Breaking Medicine News(10 mins):